# LEGN catalysts: Legend Biotech Corp PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/legn/catalysts

> Legend Biotech Corp (LEGN) has no upcoming catalysts in this calendar. The latest recorded is the Legend Biotech Corp interim data readout, January 27, 2023.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for LEGN?

Legend Biotech Corp (LEGN) has no upcoming catalysts in this calendar. The latest recorded is the Legend Biotech Corp interim data readout, January 27, 2023. SEC Form 10-K: "On January 27, 2023 we announced that CARTITUDE-4 met its primary endpoint of showing a statistically significant improvement in Progression-Free Survival ("PFS") compared to standard therapy at the study's first pre-specified interim analysis." [Calendar and source filings](https://sec-api.dev/companies/legn/catalysts)

Source: SEC Form 10-K, accession 0001801198-26-000008, https://www.sec.gov/Archives/edgar/data/1801198/000180119826000008/legn-20251231.htm (retrieved 2026-11-12). Last confirmed 2026-03-10. Cite: https://sec-api.dev/companies/legn/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | Legend Biotech Corp |
| Ticker | LEGN (Nasdaq) |
| SEC CIK | 1801198 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/legn |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| February 28, 2022 | [CARVYKTI (ciltacabtagene autoleucel) FDA approval](https://sec-api.dev/pdufa/ciltacabtagene-autoleucel) | LEGN | with relapsed or refractory multiple myeloma | completed, approved | "On February 28, 2022, the FDA approved our product CARVYKTI (cilta-cel) for the treatment of adults with RRMM who have received four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1801198/000180119825000012/legn-20241231.htm)) |
| Oct 2022 | [TECVAYLI (teclistamab) FDA approval](https://sec-api.dev/pdufa/teclistamab) | LEGN |  | completed, approved | "In that regard, Janssen, our cilta-cel collaboration partner, received FDA approval in October 2022 for Tecvalyi (teclistamab-cqyv), an off-the-shelf, T-cell directed, bispecific antibody targeting both BCMA and CD3." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1801198/000180119825000012/legn-20241231.htm)) |
| January 27, 2023 | [Legend Biotech Corp interim data readout](https://sec-api.dev/companies/legn/catalysts) | LEGN |  | completed, met | "On January 27, 2023 we announced that CARTITUDE-4 met its primary endpoint of showing a statistically significant improvement in Progression-Free Survival ("PFS") compared to standard therapy at the study's first pre-specified interim analysis." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1801198/000180119826000008/legn-20251231.htm)) |

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/legn/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "LEGN catalysts: Legend Biotech Corp PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/legn/catalysts

```bibtex
@misc{secapidev_companies_legn_catalysts_20261116,
  title        = {LEGN catalysts: Legend Biotech Corp PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/legn/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_legn_catalysts_20261116","title":"LEGN catalysts: Legend Biotech Corp PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/legn/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
